First-Ever gene therapy injected directly into hearts of patients
Disease control
Recruiting now
This is the first study in people to test a new gene therapy called TN-201 for a genetic heart condition called hypertrophic cardiomyopathy (HCM). It will involve up to 30 adults who have HCM caused by a specific gene mutation (MYBPC3). The main goals are to find a safe dose and …
Phase: PHASE1, PHASE2 • Sponsor: Tenaya Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC